1.64
Precedente Chiudi:
$1.99
Aprire:
$2.01
Volume 24 ore:
16.05M
Relative Volume:
38.96
Capitalizzazione di mercato:
$59.88M
Reddito:
-
Utile/perdita netta:
$-69.00M
Rapporto P/E:
-0.5899
EPS:
-2.78
Flusso di cassa netto:
$-55.26M
1 W Prestazione:
-9.39%
1M Prestazione:
-69.57%
6M Prestazione:
-79.40%
1 anno Prestazione:
-80.64%
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Nome
Acrivon Therapeutics Inc
Settore
Industria
Telefono
617-207-8979
Indirizzo
480 ARSENAL WAY, SUITE 100, WATERTOWN
Confronta ACRV con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
ACRV
Acrivon Therapeutics Inc
|
1.64 | 59.88M | 0 | -69.00M | -55.26M | -2.78 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-01-31 | Iniziato | KeyBanc Capital Markets | Overweight |
2024-09-16 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
2024-04-29 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
2024-03-01 | Iniziato | JMP Securities | Mkt Outperform |
2023-12-15 | Ripresa | Jefferies | Buy |
2023-10-05 | Iniziato | Maxim Group | Buy |
2023-06-02 | Iniziato | Oppenheimer | Outperform |
2023-05-08 | Iniziato | BMO Capital Markets | Outperform |
2023-04-27 | Iniziato | Ladenburg Thalmann | Buy |
2023-04-20 | Iniziato | H.C. Wainwright | Buy |
2022-12-12 | Iniziato | Cowen | Outperform |
2022-12-12 | Iniziato | Jefferies | Buy |
2022-12-12 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Acrivon Therapeutics Inc Borsa (ACRV) Ultime notizie
ACRV’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Understanding ACRV stock ratios for better investment decisions - uspostnews.com
Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025 - GlobeNewswire
Breakthrough Cancer Drug ACR-2316 Achieves 25% Tumor Reduction with Zero Safety Issues in Phase 1 Trial - Stock Titan
(ACRV) On The My Stocks Page - news.stocktradersdaily.com
April 2025's Standout Penny Stocks - simplywall.st
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Up 21.4% in March - Defense World
Down -70.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Acrivon Therapeutics, Inc. (ACRV) - NewsBreak: Local News & Alerts
Acrivon Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal moment By Investing.com - Investing.com South Africa
Acrivon Therapeutics’ SWOT analysis: oncology innovator’s stock faces pivotal moment - Investing.com India
Acrivon Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal moment - Investing.com
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.17 Average Price Target from Analysts - Defense World
Acrivon Therapeutics Reports Progress in Cancer Drug Development - TipRanks
Acrivon Therapeutics Appoints Mansoor Raza Mirza, M.D., as Chief Medical Officer - citybiz
Acrivon appoints new chief medical officer to advance cancer trials By Investing.com - Investing.com South Africa
Acrivon Therapeutics Appoints Mansoor Mirza as Medical Chief - marketscreener.com
Acrivon appoints new chief medical officer to advance cancer trials - Investing.com
Acrivon Therapeutics Appoints New Chief Medical Officer - TipRanks
Acrivon Therapeutics Appoints World-Renowned Oncology Key - GlobeNewswire
Q1 Earnings Forecast for ACRV Issued By HC Wainwright - Defense World
Acrivon Therapeutics (NASDAQ:ACRV) and Astellas Pharma (OTCMKTS:ALPMY) Head to Head Contrast - Defense World
H.C. Wainwright maintains Acrivon stock Buy rating, $19 target By Investing.com - Investing.com Australia
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know - MSN
Acrivon Therapeutics price target lowered to $10 from $18 at Oppenheimer - TipRanks
Here's Why Acrivon Therapeutics, Inc. (ACRV) is Poised for a Turnaround After Losing -52.81% in 4 Weeks - Yahoo Finance
H.C. Wainwright maintains Acrivon stock Buy rating, $19 target - Investing.com
HC Wainwright Has Lowered Expectations for Acrivon Therapeutics (NASDAQ:ACRV) Stock Price - Defense World
FY2029 Earnings Estimate for ACRV Issued By HC Wainwright - Defense World
Cantor Fitzgerald Reaffirms “Overweight” Rating for Acrivon Therapeutics (NASDAQ:ACRV) - Defense World
Acrivon Therapeutics reports Q4 EPS (60c), consensus (70c) - TipRanks
Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Breakthrough: Acrivon's Cancer Drug Shows 35% Response Rate in Hard-to-Treat Endometrial Cancer - Stock Titan
Acrivon Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Long Term Trading Analysis for (ACRV) - news.stocktradersdaily.com
Acrivon narrows focus for ACR-368 in endometrial cancer - BioWorld MedTech
JMP maintains Acrivon stock with $17 target following update By Investing.com - Investing.com Australia
Acrivon Therapeutics stock target cut to $19 by H.C. Wainwright - Investing.com South Africa
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Crude Oil Gains Over 1%; Cintas Shares Jump After Q3 Earnings - Benzinga
Nasdaq Down 1%; Dollar Tree To Sell Family Dollar Business For $1 Billion - Benzinga
Humacyte to raise $50M; Acrivon to focus on prexasertib in endometrial cancer - Endpoints News
Cantor Fitzgerald maintains Overweight on Acrivon stock By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains Overweight on Acrivon stock - Investing.com
JMP maintains Acrivon stock with $17 target following update - Investing.com
Wednesday Sector Laggards: Biotechnology, Semiconductors - Nasdaq
Acrivon Therapeutics’ SWOT analysis: innovative oncology firm’s stock potential By Investing.com - Investing.com Australia
Citizens JMP reiterates Acrivon stock with $17 target By Investing.com - Investing.com South Africa
Acrivon Therapeutics Inc Azioni (ACRV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):